ArticlePhotochemistry and photobiology2022
Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.
Article in Photochemistry and photobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Photophysical and Biological Properties of Diprotic Ruthenium(II) Complexes with Extended π-Systems.Organometallics · 2026Article
- Study of the Photophysical Properties and the DNA Binding of Enantiopure [Cr(TMP)Inorganic chemistry · 2024Article
- Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity.International journal of molecular sciences · 2023Article
- Nanoformulation of Lipophilic Osmium Photosensitizers in Liposomes and Micelles as a General Strategy for Improving Reproducibility and Reducing QuenchingPhotochemistry and photobiology · 2023Article
- Ruthenium pincer complexes for light activated toxicity: Lipophilic groups enhance toxicity.Journal of inorganic biochemistry · 2023Article
- Factors that influence singlet oxygen formation vs. ligand substitution for light-activated ruthenium anticancer compounds.Current opinion in chemical biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
We report new ruthenium complexes bearing the lipophilic bathophenanthroline (BPhen) ligand and dihydroxybipyridine (dhbp) ligands which differ in the placement of the OH groups ([(BPhen)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.